Amgen Inc.

XianYun Jiao

Julio Cesar Medina

Zice Fu

Zhihua Ma

Jiwen Liu

Yingcai Wang

Jinqian Liu

SuJen Lai

Jonathan B Houze

Frank Kayser

Wang Shen

Ming Yu

David John Kopecky

Hilary Plake Beck

Dustin L McMinn

Rajiv Sharma

Paul John Dransfield

Zhongyu Wang

Marc Vimolratana

Jiasheng Fu

Lawrence R McGee

Xiaohui Du

Xiaoqi Chen

Daqing Sun

Jeffrey Thomas Mihalic

Xuelei Yan

Michael G Johnson

Yosup Rew

Felix Gonzalez Lopez De Turiso

Jonathan Dante Low

Brian M Fox

Michael D Bartberger

Xiaodong Wang

John Eksterowicz

Jason A Duquette

Jeffrey Deignan

Julie Anne Heath

Richard V Connors

Christopher Neil Farthing

Brian Stuart Lucas

Ana Zurisadai Gonzalez Buenrostro

Steven H Olson

Darin J Gustin

Zhihong Li

Joel McIntosh

Todd J Kohn

Michael J Schmitt

Yihong Li

Michael W Gribble, Jr

Xin Huang

Benjamin Fisher

Jiang Zhu

Philip M Roveto

Matthew W Martin

David Craig McGowan

Jean E Bemis

Juan Carlos Jaen

Ryan D White

Liusheng Zhu

Timothy David Cushing

Xiaolin Hao

Leping Li

Marc Labelle

Sean P Brown

Vatee Pattaropong

Youngsook Shin

Mario G Cardozo

Joseph J Nunes

Sarah Lively

An-Rong Li

Mike Elias Lizarzaburu

Michael R Degraffenreid

Sarah Elizabeth Lively

Marie-Louise Smith

Stephen J Shuttleworth

Andrew Smith

Yong-Jae Kim

Alexander David Frenkel

Simon A Burkitt

Sven P Rasmussen

Martin J Harrison

Paul Faulder

Simon Turcotte

Richard Victor Connors

Brian Matthew Fox

Philip Marley Roveto

Dustin Mcminn

Michael Johnson

Steven Howard Olson

Darin James Gustin

Lawrence Mcgee

Jr Michael William Gribble

The present invention provides MDM2 inhibitor compounds of Formula I, 

Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer

Provided herein are compounds of formula I: wherein A, B, X, R, Rand subscript n are as defined in the following disclosure. Compositions comprising the compounds are also provided, as well as methods for their use, for example, in treatment of type 2 diabetes and type 2 diabetes-related conditions. 

Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I&#x2032;B: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Spirocyclic GPR40 modulators

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Heterocyclic GPR40 modulators

The present invention relates to furanopyridine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of modulating Lck and ACK-1 enzymes and of treating various related diseases and conditions, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, comprising administering to the mammal a therapeutically effective amount a compound of Formula I, as described above, and methods of manufacturing medicaments comprising the compound of Formula I.

Furanopyridine derivatives and methods of use

Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided herein.

Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity

Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.

Antiinflammation agents

Growing community of inventors

Belmont, CA, United States of America

XianYun Jiao